Australian Wastewater Upgrade With MemCor MBR Technology

DuPont de Nemours Investment Narrative Recap

To own DuPont, you generally need to believe in its shift toward higher value water and healthcare technologies while managing PFAS liabilities and portfolio reshaping. The Canberra MemCor win highlights DuPont’s water capabilities, but it does not materially change the near term focus on executing the Qnity separation and managing ongoing legal and cost pressures that could weigh on margins and cash flows.

Among recent announcements, the August 2026 “beat and raise” quarter, with full year net sales guidance lifted to US$7,160 million to US$7,190 million, ties most directly to this news. Stronger revenue expectations, combined with growing references to water technologies, frame contracts like the Lower Molonglo upgrade as supporting evidence for the water thesis, even as investors continue to watch profitability, legal outflows, and the impact of buybacks and restructuring on per share metrics.

Yet behind DuPont’s water wins, there is still meaningful PFAS and environmental litigation risk that investors should be aware of...

Read the full narrative on DuPont de Nemours (it's free!)

DuPont de Nemours' narrative projects $7.8 billion revenue and $919.6 million earnings by 2029. This requires 4.3% yearly revenue growth and about a $787.6 million earnings increase from $132.0 million today.

Uncover how DuPont de Nemours' forecasts yield a $172.07 fair value, a 24% upside to its current price.

Exploring Other Perspectives

DD 1-Year Stock Price Chart

Some of the most cautious analysts saw DuPont reaching about US$7.9 billion in revenue and US$888 million in earnings by 2029, which is far more pessimistic than narratives that lean on water growth and portfolio realignment, so it is worth comparing how those darker assumptions might shift after a contract win like Canberra’s MemCor upgrade.